Kaya E, Frommeyer G, Mönnig G, Eckardt L
Abteilung für Rhythmologie, Department für Kardiologie und Angiologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, Münster, Germany.
Herz. 2012 Mar;37(2):159-65. doi: 10.1007/s00059-012-3589-x.
Atrial fibrillation is the most common form of arrhythmia and one of the most frequent causes of ischemic stroke. Several new anticoagulants have recently been introduced as alternatives to vitamin-K antagonists for prophylaxis of ischemic stroke and tested in phase-3 studies for efficacy and safety. Identifying patients who will profit in particular from the new anticoagulant therapy is crucial to the clinical application of these drugs. Vernakalant and dronedarone are new antiarrhythmic drugs for rhythm control of atrial fibrillation. However, therapeutic efficacy of the new agents still has to be proven.
心房颤动是最常见的心律失常形式，也是缺血性卒中最常见的病因之一。最近，几种新型抗凝剂已被引入，作为维生素K拮抗剂预防缺血性卒中的替代药物，并在3期研究中对其疗效和安全性进行了测试。确定哪些患者将特别受益于新型抗凝治疗对于这些药物的临床应用至关重要。维纳卡兰和决奈达隆是用于控制心房颤动节律的新型抗心律失常药物。然而，这些新药的治疗效果仍有待证实。
